Efficacy study of Liraglutide as add on therapy against cardiovascular risk in type 2 diabetic patients

Trial Profile

Efficacy study of Liraglutide as add on therapy against cardiovascular risk in type 2 diabetic patients

Completed
Phase of Trial: Phase IV

Latest Information Update: 20 Feb 2018

At a glance

  • Drugs Liraglutide (Primary) ; Insulin; Metformin
  • Indications Cardiovascular disorders; Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 Feb 2018 New trial record
    • 01 Feb 2018 Results published in the Diabetes Therapy
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top